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CLASSIFICATION AND OUTCOMES IN PAPILLARY THYROID CANCER PATIENTS
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Introduction: The B-RAFV600E mutation has been associated with aggressive clinicopathological features in papillary thyroid 
cancer (PTC). However, its prognostic role is still controversial. Notwithstanding, the American Thyroid Association (ATA) 
included the B-RAFV600E mutation analysis in the 2015 risk classification system. Objectives: To evaluate the impact of the 
B-RAFV600E mutation on the ATA risk classification and outcomes of patients with PTC. Methods: PTC unselected indivi-
duals from a cohort attending the thyroid outpatient clinic of a university based hospital who had analysis of the B-RAFV600E 
mutation were included in this study. Patients were classified as having low, intermediate and high recurrence risk according to 
the 2009 ATA risk classification system. The mutation was assessed by PCR and sequencing. The impact of mutation analysis 
was evaluated in the reclassification on the ATA risk system and disease outcomes. Persistent disease was defined as the pre-
sence of clinical or radiological and/or biochemical disease (thyroglobulin under suppression > 1 ng/mL and/or stimulated 
thyroglobulin > 2 ng/mL). Results: Of the 133 patients evaluated, 106 (79.7%) were women, and 45 (33.5%) presented the 
B-RAFV600E mutation. Regarding the extension of disease, median tumor size was 1.7 cm (P25-75 1.0-3.0); 66 (49.6%) pa-
tients had lymph node and 9 (6.8%) had distant metastases. According to the 2009 ATA risk system, the risk level was classified 
as low, intermediate and high in 57 (42.9%), 52 (39.1%) and 24 (18.0%) patients, respectively. The data on B-RAF mutation 
reclassified 9 (6.8%) patients from low to intermediate risk. After a median follow-up of 6.0 years (P25-75 3.0-9.0), disease 
status was available for 115 patients: 84 (73%) patients were disease-free and 31 (27%) had persistent disease. Regarding BRAF 
mutation status, the prevalence of persistent disease was similar in patients with positive and negative mutation: 28.9% vs. 26.0% 
(P = 0.90). In the multivariate analysis, the mutation was also not associated with persistent disease status (RR 1.04; 95% CI 
0.62-1.76). Interestingly, none of the patients who had the risk increased from low to intermediate showed persistent disease 
on follow-up. Conclusion: Although B-RAFV600E mutation analysis reclassified a small proportion of patients, it does not 
add in prediction of outcomes in patients with PTC. The benefit of including the B-RAFV600E mutation analysis in clinical 
practice must be considered.
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Introduction: Vandetanib (VDT), a tyrosine kinase inhibitor (TKI) that targets ret, VEGFR2 and EGFR, is effective in pa-
tients with medullary thyroid cancer (MTC). Despite evidence of improved progression free survival (PFS) and high overall 
response rate in clinical trials, data on the use of VDT in the real-life clinical setting remain limited. Objective: We retrospec-
tively reviewed the efficacy of VDT in locally advanced or metastatic MTC treated at Gustave Roussy. Methods: Sixty-five 
patients were treated with VDT between 2006 and 2015, as first line treatment in 50 patients and as second-line treatment in 
11. Four patients were excluded for incomplete data. Results: There were 61 patients (74% men). Mean age was 46 years and 
7 had hereditary MTC. 66% had metastatic disease in the mediastinum, liver (79%), bones (72%), or lung (59%), and 2 had only 
locally advanced disease. At the time of evaluation, with a median time of 40 months since VDT treatment initiation and a me-
dian treatment duration of 27 months (range 1,1-131 months), 10 patients were still receiving VDT for a median duration of 
103 months (range 13-128 months). 36/61 patients discontinued treatment for disease progression after a median treatment 
duration of 24 months (range 1,8-80 months) and 13 patients for adverse events. PFS at 2 and 5 years were 70% (95% CI 59%-
83%) and 38% (95% CI 24-54%), respectively. Best tumor response was a complete response in 3 patients, a partial response in 
28 (46%), stable disease in 27 (44%), and progression in 3 patients (5%). Median decreases in tumor size according to RECIST 
were -18% and -38% for 1st and 2nd line VDT, respectively. Conclusions: These findings suggest that the introduction of VDT 
as molecular-targeted agent resulted in favorable outcomes in MTC patients. Support: Capes.
